

## **ASX Announcement**

**30 October 2020**

### **Annual Report Additional Information**

**Regeneus Ltd (ASX: RGS) (Regeneus or the Company)**, a clinical-stage regenerative medicine company, provides the additional information set out on the following page as part of the Annual Report lodged with the ASX on 28 August 2020.

Regeneus inadvertently omitted to include this information in the FY20 Annual Report.

The corrected full Annual Report is available on Regeneus' website [www.regeneus.com.au](http://www.regeneus.com.au).

**-ENDS-**

#### **About Regeneus**

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address unmet medical needs in human health markets with a focus on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit [www.regeneus.com.au](http://www.regeneus.com.au) for more information.

#### **Authorisation & Additional information**

This announcement was authorised by the Board of Directors of Regeneus Ltd

#### **Investor and Media Contact**

WE Communications  
T: 02 9237 2805  
E: [WE-AURegeneus@we-worldwide.com](mailto:WE-AURegeneus@we-worldwide.com)

# Additional shareholder information

Additional information required by the ASX Limited Listing Rules and not disclosed elsewhere in this report is set out below. The information is effective 27 August 2020

## Corporate governance statement

In accordance with the ASX principles and recommendations, Regeneus Ltd's corporate governance statements can be reviewed on the Company website at:

## Substantial shareholders

The number of substantial shareholders and their associates are set out below:

Shareholder	Number of shares
Kirman 2 Pty Ltd	15,760,892

## Voting rights

### Ordinary shares

On a show of hands, every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

### Options

No voting rights

## Distribution of equity security holders

Holding	Shares	Options
100,001 and over	245,403,727	17,001,674
10,001 to 100,000	29,605,769	-
5,001 to 10,000	2,069,125	-
1,001 to 5,000	737,275	-
1 to 1,000	9,092	-
	277,824,988	17,001,674
Unmarketable parcels	1,201,038	

## Buy back of shares

There is no buy back of shares on offer

## Unissued equity securities

Options issued under the options plans total 17,001,674

## Ordinary shares

Twenty largest shareholders	Number held	% of issued shares
HSBC CUSTODY NOMINEES	21,150,881	7.61
BNP PARIBAS NOMINEES	18,519,765	6.67
CITICORP NOMINEES PTY LIMITED	16,931,497	6.09
J P MORGAN NOMINEES AUSTRALIA LIMITED	11,356,673	4.09
EAGLE FUND SP1 LLP	9,437,872	3.40
MR THOMAS MECHTERSHEIMER	6,133,433	2.21
SMC CAPITAL PTY LTD	5,216,726	1.88
MRS JULIA CAROLINE HUGHES	4,624,304	1.66
MR JOHN DOMINIC MARTIN	4,384,682	1.58
MLB HOLDINGS PTY LTD	3,500,000	1.26
SHAUN SUNDBERG	3,125,000	1.12
MAXIMUM (NQ) PTY LTD	3,041,666	1.09
DR MARC RONALD WILKINS	2,985,161	1.07
BUBBLING WELLS PTY LTD	2,500,000	0.90
MR PIERRE FREDERIC MALOU	2,166,538	0.78
MCGUIRE FAMILY HOLDINGS PTY LTD	2,050,000	0.74
KBROSS PTY LTD	2,000,000	0.72
BACAU PTY LTD	1,940,732	0.70
MS ROSEMARY KAREN MARTIN	1,863,642	0.67
LIDDLE INVESTMENTS GROUP	1,781,000	0.64
<b>Total</b>	<b>124,709,572</b>	<b>44.89</b>
<b>Balance of register</b>	<b>153,115,416</b>	<b>55.11</b>
<b>Grand total</b>	<b>277,824,988</b>	<b>100.00</b>